Skip to main navigation

Corporate Links

  • Our Technology
    • Corporate Presentation
    • Presentations & Publications
  • Pipeline
    • PSA-Associated Cancers
    • HOT Program
    • HER2-Associated Cancers
    • NEO Program
    • HPV-Associated Cancers
    • Patient Stories
  • Partners
  • About Us
  • Investors
White Logo Color Logo

Corporate Links

  • Our Technology
    • Corporate Presentation
    • Presentations & Publications
  • Pipeline
    • PSA-Associated Cancers
    • HOT Program
    • HER2-Associated Cancers
    • NEO Program
    • HPV-Associated Cancers
    • Patient Stories
  • Partners
  • About Us
  • Investors

Corporate Presentation

Corporate Presentation

Corporate Presentation - May 2022

UPLOADED:

May 10, 2022

Gutierrez AA. Clinical activity and immunogenicity of a neoantigen immunotherapy in non-small cell lung cancer. Neoantigen Based Therapies Summit. Weaponizing Vaccines and Cell Based Immunotherapies. October 28, 2021. Virtual Meeting

UPLOADED:

October 28, 2021

Gutierrez AA. Can neoantigen immunotherapies reverse resistance to PD-1 inhibitors and progression in NSCLC?. Non-Small Cell Lung Cancer Drug Development Summit. Virtual meeting. July 15, 2021

UPLOADED:

July 15, 2021

Haigentz M, et.al. A phase 1 study of an off the shelf, multi-neoantigen vector (ADXS-503) in patients with metastatic non-small cell lung cancer (NSCLC) progression on pembrolizumab as last therapy. 2021 ASCO Annual meeting. June 4-8, 2021. Abst # 2616

UPLOADED:

June 4, 2021

Monhanram V, et.al. Evaluation of total PD-1 expression using multi-color flow cytometry in metastatic non-small Cell lung cancer patients treated with multi-neoantigen vector (ADXS-503) alone and in combination of pembrolizumab to assess T-cell & T-cell

UPLOADED:

March 26, 2021

IO 360 Presentation

UPLOADED:

February 27, 2020

Immuno-Oncology 360° Conference Presentation

UPLOADED:

February 6, 2019

STAY TUNED

Mailing List

Sign up for email alerts for Press Releases and Advaxis' breaking news.

SOCIAL

Follow Us

Stay up to date on the latest events, news, and happenings on Advaxis and Immunotherapy.

Corporate Footer Links

    Our Lm Technology™
  • Intellectual Property
  • The Advaxis Difference
  • Corporate Presentation
  • Presentations and Publications
    Pipeline
  • PSA-Associated Cancers
  • HOT Program
  • HER2-Associated Cancers
  • NEO Program
  • HPV-Associated Cancers
  • Patient Stories
    Partners
  • Academic Institutions
  • Clinical Partners
  • Licensing Agreements
    About Us
  • Board of Directors
  • Careers
  • In the News
  • Leadership
  • Our Values
  • Scientific Advisory
    Investors
  • News & Events
  • Stock Information
  • Corporate Governance
  • Financial Information
  • Shareholder Services
  • Videos
Color Logo

Corporate Footer Links

    Our Lm Technology™
  • Intellectual Property
  • The Advaxis Difference
  • Corporate Presentation
  • Presentations and Publications
    Pipeline
  • PSA-Associated Cancers
  • HOT Program
  • HER2-Associated Cancers
  • NEO Program
  • HPV-Associated Cancers
  • Patient Stories
    Partners
  • Academic Institutions
  • Clinical Partners
  • Licensing Agreements
    About Us
  • Board of Directors
  • Careers
  • In the News
  • Leadership
  • Our Values
  • Scientific Advisory
    Investors
  • News & Events
  • Stock Information
  • Corporate Governance
  • Financial Information
  • Shareholder Services
  • Videos
Copyright © 2022 All Rights Reserved
Color Logo